Synovial sarcoma X breakpoint protein 3 (SSX3)

Synovial sarcoma X breakpoint protein 3 (SSX3) is a member of the SSX family of cancer–testis antigens, which are a group of highly homologous nuclear proteins normally restricted to germline tissues (primarily testis) but aberrantly expressed in a variety of human cancers[1][2][3]. SSX3 is characterized by a Kruppel-associated box (KRAB) domain and a strong transcriptional repressor domain, and like other SSX proteins, it functions mainly as a transcriptional repressor via interaction with chromatin remodeling complexes such as Polycomb group proteins[2]. While the SSX3 gene is highly homologous to other SSX family members (notably SSX1 and SSX2), unlike SSX1/2 it does not form gene fusions (e.g., SS18-SSX) implicated in synovial sarcoma pathogenesis[1]. SSX proteins, including SSX3, have been shown to promote tumor cell proliferation and survival, likely through modulation of MAPK/Erk, Akt, and Wnt/β-catenin signaling pathways, and may also play a role in controlling epithelial–mesenchymal transition and invasion[2]. SSX family antigen expression in tumors is associated with more advanced disease and poorer prognosis, making them relevant as both potential therapeutic targets (particularly for cancer immunotherapy) and as biomarkers for prognosis and patient selection[1][2][4]. No approved drugs directly target SSX3, but the SSX family as a whole is under active investigation as an immunotherapeutic target. SSX3 expression in normal adult tissues is believed to be largely testis-restricted, reducing the risk of off-tumor toxicity, although care must be taken to avoid inducing immune responses against germline cells[1][2][3].

Other names

SSX family member 3SSX3Cancer/testis antigen 5.3CT5.3Protein SSX3Kruppel-associated box containing gene product SSX3synovial sarcoma X breakpoint 3cancer/testis antigen 5.3

Immunotherapy via T-cell recognition (cancer vaccines and adoptive immunotherapy exploiting SSX-derived peptides as tumor antigens)